Imbian Lab

History

2024: Launch of a pharmaceutical enterprise for the production of rapid tests and medical products

On September 9, 2024, the administration of the Slavyansky district of the Krasnodar Territory announced the creation of a pharmaceutical enterprise for the production of medical devices, express tests and biologically active additives (dietary supplements). The project is being implemented by Imbian LAB, which specializes in the development and production of diagnostic reagent kits with enzyme-linked immunosorbent (ELISA), immunochromatographic (IHA) methods, as well as the polymerase chain reaction (PCR) method.

The new production was launched on the basis of the reconstructed mechanical repair plant in Slavyansk-on-Kuban. In January 2023, an investment agreement worth 3 billion rubles on the implementation of the project was concluded between the district administration and Imbian LAB. As of the beginning of September 2024, 210 million rubles were invested in the project. According to the results of 2023, the volume of tax deductions to the budgets of all levels amounted to 17.9 million rubles. The company plans to create at least 70 new jobs.

source = Telegram channel of the head of the Slavyansky district Roman Sinyagovsky

The head of the Slavyansky district, Roman Sinyagovsky, notes that the Imbiyan LAB investment project makes a significant contribution to the development of the municipality's economy, contributes to an increase in the number of jobs in Slavyansk-on-Kuban and an increase in the revenue side of the local budget. The production of dietary supplements in the form of teas based on plant raw materials has already been mastered. When the project is fully implemented, the company will begin to produce more than 200 thousand units of products annually.

For the economy of the Slavyansky district, new investments and production are a very important indicator. These are additional jobs, an increase in local budget revenues, improvement and development of the territory of our municipality as a whole, the local administration said in a statement.[1]

2022: Investing 400 million rubles in infection detection systems

As it became known in February 2022, the Novosibirsk developer of medical tests "Imbian Lab" will invest 400 million rubles in systems for determining infections, including coronavirus COVID-19. The production of new products is planned to be established in the special economic zone (SEZ) "Technopolice" Moscow. "

The company will produce medical tests designed to detect a large number of infections and abnormalities in human health. Including 15 types of test systems for the presence of COVID-19. It is planned that the enterprise will produce about 12 million units of products per month, "said Vladimir Efimov, Deputy Mayor of Moscow for Economic Policy and Property and Land Relations, whose words are quoted on the official website of the capital's mayor.

Imbiyan Lab invests 400 million rubles in infection detection systems

The medical test systems that will be produced at the enterprise are focused on the market of Moscow and the regions. Some of the products are planned to be exported.

The total area of ​ ​ the new enterprise is 2.5 thousand square meters. Half of the territory is occupied by "clean rooms" with a laboratory, a production site for research, development and testing. The second half was taken under the labeling and equipment of finished products, auxiliary work.

Imbian Lab specializes in the development and supply of diagnostic kits with enzyme immunosorbent (ELISA), immunochromatographic (IHA) methods, as well as the polymerase chain reaction (PCR) method. The supplier's portfolio includes rapid tests for antigen and antibodies to the SARS-CoV-2 coronavirus, medical tests for hepatitis C, urogenital and TORCH infections under the Imbian brand. The company is developing its own immunochips - test systems for the simultaneous detection of antibodies and antigens to pathogens of various types of infections in human serum and plasma.^[2]

Notes